# TAFINLAR
> **NDA217514** · New Drug Application · Sponsor: NOVARTIS · Approved 2023-03-16
## Drug
- **FDA Application Number:** NDA217514
- **Application type:** New Drug Application
- **Brand name:** TAFINLAR
- **Generic name:** DABRAFENIB
- **Active ingredients:** DABRAFENIB MESYLATE
- **Dosage form:** CAPSULE
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** NOVARTIS
- **Manufacturer:** Novartis Pharmaceuticals Corporation
- **First approval:** 2023-03-16
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217514)
---
*MORVS · CC0 1.0*